MedKoo Cat#: 145770 | Name: AUT-00206

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AUT-00206 is an investigational compound developed as a positive modulator of Kv3.1 and Kv3.2 potassium channels. These channels are crucial for the proper functioning of GABAergic interneurons, which play a significant role in cognitive processes and neuronal excitability. By enhancing the activity of these channels, AUT-00206 aims to restore the balance of neuronal activity, potentially addressing cognitive and negative symptoms associated with schizophrenia. In preclinical studies, AUT-00206 has demonstrated the ability to normalize gamma oscillations and improve cognitive function in animal models.

Chemical Structure

AUT-00206
AUT-00206
CAS#1380696-64-9

Theoretical Analysis

MedKoo Cat#: 145770

Name: AUT-00206

CAS#: 1380696-64-9

Chemical Formula: C20H20N4O4

Exact Mass: 380.1500

Molecular Weight: 380.40

Elemental Analysis: C, 63.15; H, 5.30; N, 14.73; O, 16.82

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
AUT-00206; AUT00206; AUT 00206;
IUPAC/Chemical Name
5,5-dimethyl-3-(2-((7-methyl-2H-spiro[benzofuran-3,1'-cyclopropan]-4-yl)oxy)pyrimidin-5-yl)imidazolidine-2,4-dione
InChi Key
JYHHQTRVJFMEGR-UHFFFAOYSA-N
InChi Code
1S/C20H20N4O4/c1-11-4-5-13(14-15(11)27-10-20(14)6-7-20)28-17-21-8-12(9-22-17)24-16(25)19(2,3)23-18(24)26/h4-5,8-9H,6-7,10H2,1-3H3,(H,23,26)
SMILES Code
CC1=C2OCC3(CC3)C2=C(OC4=NC=C(C=N4)N5C(=O)NC(C)(C)C5=O)C=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 380.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Angelescu I, Kaar SJ, Marques TR, Borgan F, Veronesse M, Sharman A, Sajjala A, Deakin B, Hutchison J, Large C, Howes OD. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. J Psychopharmacol. 2022 Sep;36(9):1061-1069. doi: 10.1177/02698811221122031. PMID: 36164687; PMCID: PMC9554157. 2: Kaar SJ, Angelescu I, Nour MM, Marques TR, Sharman A, Sajjala A, Hutchison J, McGuire P, Large C, Howes OD. The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia. Psychopharmacology (Berl). 2022 Oct;239(10):3313-3323. doi: 10.1007/s00213-022-06216-3. Epub 2022 Sep 12. PMID: 36094619; PMCID: PMC9481488. 3: Musselman M, Huynh E, Kelshikar R, Lee E, Malik M, Faden J. Potassium channel modulators and schizophrenia: an overview of investigational drugs. Expert Opin Investig Drugs. 2023 Jan-Jun;32(6):471-477. doi: 10.1080/13543784.2023.2219385. Epub 2023 Jun 9. PMID: 37247333. 4: Feng H, Clatot J, Kaneko K, Flores-Mendez M, Wengert ER, Koutcher C, Hoddeson E, Lopez E, Lee D, Arias L, Liang Q, Zhang X, Somarowthu A, Covarrubias M, Gunthorpe MJ, Large CH, Akizu N, Goldberg EM. Targeted therapy improves cellular dysfunction, ataxia, and seizure susceptibility in a model of a progressive myoclonus epilepsy. Cell Rep Med. 2024 Feb 20;5(2):101389. doi: 10.1016/j.xcrm.2023.101389. Epub 2024 Jan 23. PMID: 38266642; PMCID: PMC10897515. 5: Stubbendorff C, Hale E, Day HLL, Smith J, Alvaro GS, Large CH, Stevenson CW. Pharmacological modulation of Kv3 voltage-gated potassium channels regulates fear discrimination and expression in a response-dependent manner. Prog Neuropsychopharmacol Biol Psychiatry. 2023 Dec 20;127:110829. doi: 10.1016/j.pnpbp.2023.110829. Epub 2023 Jul 12. PMID: 37451593. 6: Kaar SJ, Nottage JF, Angelescu I, Marques TR, Howes OD. Gamma Oscillations and Potassium Channel Modulation in Schizophrenia: Targeting GABAergic Dysfunction. Clin EEG Neurosci. 2024 Mar;55(2):203-213. doi: 10.1177/15500594221148643. Epub 2023 Jan 2. PMID: 36591873; PMCID: PMC10851642.